BTKi has become the standard treatment regimen for CLL/SLL，there is a lack of large-scale real-world studies on the use status and related influencing factors of BTK inhibitors. Therefore, we plan to conduct this multicenter retrospective cross-sectional study to understand the current situation of BTK inhibitor treatment for CLL/SLL patients in China and the related influencing factors, and to explore more suitable treatment patterns based on this.
Study Type
OBSERVATIONAL
Enrollment
1,000
BTKi can refer to Orelabrutinib, Ibrutinib, Zanubrutinib, and Acalabrutinib
Department of Haematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital
Nanjin, Jiangsu, China
RECRUITINGPatient characteristics of those receiving BTKi treatment
Describe the patient characteristics of those receiving BTKi treatment, including age, gender, etc
Time frame: up to one year
overall response rate
Assessed according to the iwCLL2018 criteria
Time frame: up to one year
Incidence of adverse reactions
Assessed according to the CTCAE 5.0 criteria
Time frame: up to one year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.